Get the Stockscreener App
0.00
100.00%
-1.19
After Hours:
.10
0.10
+
Orgenesis Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$1.19
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$1.04M
Net Income/Loss:
$-49.01M
P/E Ratio:
0.00
EPS:
-11.109
Net Cash Flow:
$-17.34M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.00
Orgenesis Inc Stock (ORGS) Company Profile
Compare ORGS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGS
Orgenesis Inc
|
0.00 | 0 | 1.04M | -49.01M | -17.34M | -11.11 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Orgenesis Inc Stock (ORGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-18 | Initiated | Dawson James | Buy |
Orgenesis Inc Stock (ORGS) Latest News
Orgenesis, Inc. Revenue Breakdown – OTC:ORGS - TradingView
Price to earnings forward of Orgenesis, Inc. – OTC:ORGS - TradingView
Future Perspectives: Key Trends Shaping the Cell Therapy Human Raw Materials Market Until 2029 - openpr.com
Top Companies Developing Cell Therapy Treatments For Diabetes in 2026 - BioInformant
Zeo ScientifiX, Inc. (ZEOX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Orgenesis stock reflects restructuring as revenue pivots toward POCare platform - Ad-hoc-news.de
If You Invested $1,000 in Vaxxinity, Inc. (VAXX) - Stock Titan
Orgenesis focuses on cell therapy manufacturing as investors weigh long-term growth prospects - Ad-hoc-news.de
Impact of buying a Hyundai or Genesis - WKRG
Orgenesis adjusts its cell-therapy focus, shares trade quietly on Nasdaq - AD HOC NEWS
Orgenesis Shareholders Approve Major Charter and Stock Increase - TipRanks
SOPAQ Stock Price and Chart — OTC:SOPAQ - TradingView
Orgenesis Inc stock (US68621F1021): delisting to OTC puts spotlight on business model and risks - AD HOC NEWS
UZX Stock Price and Chart — NASDAQ:UZX - TradingView
Orgenesis stock (US68621F1021): cell and gene therapy specialist updates investors amid ongoing rest - AD HOC NEWS
Orgenesis Inc. (ORGS) Surges 79,400% on Penny Stock Rebound - Meyka
Corvus Pharmaceuticals Reports Positive Final Phase 1 Results for Soquelitinib in Atopic Dermatitis at SID 2026 Annual Meeting 16 - Minichart
Orgenesis stock (US68621F1021): Recent clinical trial progress draws investor attention - AD HOC NEWS
MSN Money - MSN
Orgenesis | DEF 14A: Definitive information statements - Moomoo
Competitive Analysis: Key Market Leaders and Emerging - openPR.com
ACNB Corporation Files Q1 2026 Results and Press Release with SEC – Financial Statements and Key Disclosures - Minichart
ALP Stock Price and Chart — NASDAQ:ALP - TradingView
ORGS | ORGENESIS INC Insider Trading - Quiver Quantitative
Viral Vector Production (Research-use) Market Size to Surpass USD 8.51 Billion by 2035 - BioSpace
Gold, Silver Futures Rise Pre-Bell as Sliding Crude Oil Futures Help Limit Inflation Concerns - marketscreener.com
Orgenesis Inc stock (US68621F1021): Is its cell therapy pivot strong enough to unlock biotech upside - AD HOC NEWS
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
ORGS (Orgenesis) PB Ratio : (As of Mar. 31, 2026) - gurufocus.com
Stock List: Research Stocks from Around the World - GuruFocus
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
CYAB Stock Price and Chart — NASDAQ:CYAB - TradingView
Orgenesis Inc. 2024 Annual 10-K Report: Financials, Equity, and Major Agreements Overview - Minichart
ORGS: Severe liquidity issues and a $49M net loss raise substantial doubt about ongoing operations - TradingView
Orgen 2023 Form 10-K: $1.035M Revenue, $(49.01)M Net Loss - TradingView
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio - StreetInsider
Okogen Expands Antiviral Pipeline with Ranpirnase Acquisition, Targeting Multiple Therapeutic Areas - citybuzz.co
Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc.. - marketscreener.com
Orgenesis Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Orgenesis Inc stock advances on cellular therapy breakthroughs amid biotech funding surge - ad-hoc-news.de
Orgenesis Inc stock advances on new cell therapy partnership amid biotech rally - AD HOC NEWS
Orgenesis Expands Board and Appoints New Chief Financial Officer - The Globe and Mail
Orgenesis appoints new directors and chief financial officer - Investing.com South Africa
Orgenesis appoints new directors and chief financial officer By Investing.com - Investing.com Australia
Orgenesis adds Adam Pelavin and Yaron Adler to board; Doug Karriker named CFO - TradingView
Orgenesis Inc. Appoints Doug Karriker as Chief Financial Officer, Effective March 10, 2026 - marketscreener.com
YMT Stock Price and Chart — NASDAQ:YMT - TradingView
Patience Required for Orgenesis Investors as Strategic Model Takes Shape - AD HOC NEWS
The Truth About Orgenesis Inc (ORGS): Tiny Biotech, Huge Hype – But Is It Worth Your Money? - AD HOC NEWS
Nasdaq proposes 'fast entry' rule to speed up index inclusion of large new listings - marketscreener.com
Orgenesis Inc Stock (ORGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.07%
Cap:
|
Volume (24h):